Yasmeen Rahimi
Stock Analyst at Piper Sandler
(1.43)
# 1516
Out of 5,329 analysts
109
Total ratings
37.50%
Success rate
15.28%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
SLNO Soleno Therapeutics | Maintains: Overweight | 93 145 | 75.12 | 93.02% | 2 | Apr 24, 2025 | |
EWTX Edgewise Therapeutic... | Maintains: Overweight | 51 51 | 16.71 | 205.21% | 4 | Apr 2, 2025 | |
LXRX Lexicon Pharmaceutic... | Maintains: Overweight | 10 6 | 0.72 | 733.33% | 2 | Mar 7, 2025 | |
AVTX Avalo Therapeutics | Initiates Coverage On: Overweight | 48 | 5.04 | 852.38% | 1 | Feb 28, 2025 | |
PRTA Prothena Corp | Maintains: Overweight | 94 110 | 8.72 | 1161.47% | 2 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 93 | 30.21 | 207.85% | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 75 | 8.99 | 734.26% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 7 | 0.78 | 797.44% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 52 26 | 7.5 | 246.67% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 37 37 | 19.99 | 85.09% | 2 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 26 | 1.47 | 1668.71% | 2 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 20 | 2.58 | 675.19% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 28 28 | 1.17 | 2293.16% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 97 97 | 33.6 | 188.69% | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 270 270 | 38.16 | 607.55% | 3 | Jul 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 76 | 19.68 | 286.18% | 1 | Jun 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 25 | 5.2 | 380.77% | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 30 | 14.44 | 107.76% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 6 12 | 4.75 | 152.63% | 2 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 31 36 | 72.25 | -50.17% | 2 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 0.65 | 1284.62% | 1 | Apr 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 180 180 | 18.54 | 870.87% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 | 1.04 | 1342.31% | 1 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 336 | 326.72 | 2.84% | 3 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 16 | 3.25 | 392.31% | 2 | Mar 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 80 | 21.72 | 268.32% | 1 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 33 33 | n/a | n/a | 5 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 250 40 | n/a | n/a | 3 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 58 93 | 27.31 | 240.53% | 3 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 65 | 17.89 | 263.33% | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 57 | 15.96 | 257.14% | 2 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 67 | 3.94 | 1600.51% | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 35 | 45.16 | -22.5% | 3 | Jul 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 138 200 | n/a | n/a | 3 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22 | 0.33 | 6566.67% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 41 | n/a | n/a | 1 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 87 | 6.08 | 1330.92% | 3 | Feb 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 75 175 | 6.03 | 2802.16% | 4 | Jan 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 18 13 | n/a | n/a | 2 | Oct 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 73 | n/a | n/a | 1 | Aug 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 50 72 | 43.03 | 67.33% | 3 | Jun 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 63 27 | 1.61 | 1577.02% | 1 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 54 19 | 8.13 | 133.7% | 2 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 50 | 1.38 | 3523.19% | 1 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | 0.5 | 7900% | 1 | Aug 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 0.43 | 4086.05% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 220 45 | n/a | n/a | 2 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 81 | n/a | n/a | 3 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 77 | 12.54 | 514.04% | 1 | Aug 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 420 | 10.99 | 3721.66% | 1 | Aug 26, 2020 |